Thomas Cornfield
Overview
Explore the profile of Thomas Cornfield including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
399
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Westcott F, Nagarajan S, Parry S, Savic D, Green C, Marjot T, et al.
Eur J Endocrinol
. 2024 Oct;
191(4):463-472.
PMID: 39353069
Objective: Fasting hyperglycemia and hypertriglyceridemia are characteristic of insulin resistance (IR) and rodent work has suggested this may be due to selective hepatic IR, defined by increased hepatic gluconeogenesis and...
2.
Othonos N, Pofi R, Arvaniti A, White S, Bonaventura I, Nikolaou N, et al.
Nat Commun
. 2023 Feb;
14(1):1025.
PMID: 36823106
Glucocorticoids prescribed to limit inflammation, have significant adverse effects. As 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) regenerates active glucocorticoid, we investigated whether 11β-HSD1 inhibition with AZD4017 could mitigate adverse glucocorticoid effects...
3.
Hazlehurst J, Lim T, Charlton C, Miller J, Gathercole L, Cornfield T, et al.
Metabol Open
. 2022 Mar;
14:100177.
PMID: 35313531
Background And Aims: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver condition. It is tightly associated with an adverse metabolic phenotype (including obesity and type 2 diabetes)...
4.
Green C, Marjot T, Walsby-Tickle J, Charlton C, Cornfield T, Westcott F, et al.
Eur J Endocrinol
. 2022 Jan;
186(3):367-377.
PMID: 35038311
Objective: Metformin is a first-line pharmacotherapy in the treatment of type 2 diabetes, a condition closely associated with non-alcoholic fatty liver disease (NAFLD). Although metformin promotes weight loss and improves...
5.
Parry S, Rosqvist F, Peters S, Young R, Cornfield T, Dyson P, et al.
Ups J Med Sci
. 2021 Sep;
126.
PMID: 34471486
Background: The fatty acid (FA) composition of blood can be used as an objective biomarker of dietary FA intake. It remains unclear how the nutritional state influences the FA composition...
6.
Hunter A, Pelekanou C, Barron N, Northeast R, Grudzien M, Adamson A, et al.
Elife
. 2021 Aug;
10.
PMID: 34350828
The circadian clock component NR1D1 (REVERBα) is considered a dominant regulator of lipid metabolism, with global deletion driving dysregulation of white adipose tissue (WAT) lipogenesis and obesity. However, a similar...
7.
Hunter A, Pelekanou C, Adamson A, Downton P, Barron N, Cornfield T, et al.
Proc Natl Acad Sci U S A
. 2020 Sep;
117(41):25869-25879.
PMID: 32989157
The nuclear receptor REVERBα is a core component of the circadian clock and proposed to be a dominant regulator of hepatic lipid metabolism. Using antibody-independent ChIP-sequencing of REVERBα in mouse...
8.
Parry S, Rosqvist F, Cornfield T, Barrett A, Hodson L
Clin Nutr
. 2020 Aug;
40(3):1108-1114.
PMID: 32753348
Background: It has been suggested that dietary polyunsaturated fatty acids (PUFA) are partitioned into oxidation pathways to a greater extent than dietary saturated fatty acids (SFA). Whilst this has been...
9.
Gunn P, Pramfalk C, Millar V, Cornfield T, Hutchinson M, Johnson E, et al.
Physiol Rep
. 2020 Jul;
8(13):e14482.
PMID: 32643289
Background And Aims: Nonalcoholic fatty liver disease (NAFLD) begins with steatosis, where a mixed macrovesicular pattern of large and small lipid droplets (LDs) develops. Since in vitro models recapitulating this...
10.
Othonos N, Marjot T, Woods C, Hazlehurst J, Nikolaou N, Pofi R, et al.
J Clin Endocrinol Metab
. 2020 Jun;
105(9).
PMID: 32594135
Context: Glucocorticoids (GCs) are commonly prescribed, but their use is associated with adverse metabolic effects. 5α-reductase inhibitors (5α-RI) are also frequently prescribed, mainly to inhibit testosterone conversion to dihydrotestosterone. However,...